A recent Haematology digest,
as sent to subscribers

Study Type: Preclinical experimental study (murine ex vivo expansion and transplantation models).

Key Question: What molecular mechanisms enable functional ex vivo expansion of haematopoietic stem cells (HSCs), and can they be harnessed in aged HSCs?

Key Findings:

• Lin28b, normally restricted to fetal haematopoiesis, is re-expressed during ex vivo expansion of young adult HSCs. Its expression level correlates with reconstitution potential (highest in fetal liver and young bone marrow HSCs).
• Aged HSCs fail to upregulate Lin28b robustly and show unstable post-transplant reconstitution; Lin28b-deficient HSCs acquire ageing-associated molecular and functional features after expansion.
• Lin28b overexpression during expansion enhanced reconstitution potential of aged HSCs (effect sizes not reported in abstract).

Clinical Relevance: Identifies a potential target for expanding or rejuvenating HSCs, which could eventually benefit graft-limited settings such as cord blood transplantation or gene therapy, although this is far from clinical application in the NHS.

Limitations: Murine data only, with no human HSC validation, so translational relevance remains unproven.

Study Type: Preclinical laboratory study (murine/cell-line models, proteomics, human cohort transcript validation, and ex vivo patient samples).

Key Question: What mechanisms drive the aggressive phenotype of CSF3R compound mutations in chronic neutrophilic leukaemia (CNL), and are they therapeutically targetable?

Key Findings:

• Compound CSF3R mutations (activating point plus truncating, ~25% of CSF3R-mutant CNL) caused a more hyperproliferative leukaemia than single mutations, with markedly greater STAT5 and ERK1/2 activation.
• Proteomics showed enrichment of MYC and mTOR pathways; PIM1 was the most differentially expressed protein. High STAT activity increased PIM transcription, and PIM overexpression stabilised MYC protein.
• PIM inhibition reversed MYC stabilisation and showed activity in human cell lines and CNL patient samples (quantitative effect sizes not given in the abstract).

Clinical Relevance: CSF3R-mutant CNL has limited options beyond ruxolitinib, so PIM inhibition is a candidate strategy for compound-mutant disease that may merit future trial consideration, though no UK access or clinical data exist yet.

Limitations: Evidence is entirely preclinical, with small patient-sample numbers and no in vivo clinical efficacy or safety data in humans.

Study Type: Preclinical experimental study (primarily murine, with limited in vitro human HSC validation).

Key Question: How do circadian cues, including melatonin, coordinate mitochondrial and metabolic programs in primitive HSCs, and does this affect stem cell function?

Key Findings:

• At night, peak melatonin was associated with reduced mitochondrial membrane potential, raised mitochondrial ROS, and DRP1/PINK1-dependent mitophagy, with enhanced long-term repopulating capacity in mouse pHSCs.
• Glycolytic reprogramming (increased glucose uptake, GLUT1, AMPK, HIF1α) was driven by systemic circadian inputs such as feeding cues and Wnt/β-catenin, distinct from melatonin-driven mitochondrial remodelling. Cell and nuclear size also fluctuated, linked to lamin A/C phosphorylation.
• Some glycolytic features were conserved in human HSCs; in vitro melatonin reduced mitochondrial membrane potential and cell size in human pHSCs. Abstract gives no effect sizes or sample sizes.

Clinical Relevance: Findings raise the possibility that time of day of HSC collection or transplantation, or melatonin modulation, could influence graft fitness, though this is hypothesis-generating only.

Limitations: Evidence is predominantly murine with only in vitro human validation, and no clinical or in vivo human transplant data are presented.

Study Type: Preclinical mechanistic study (likely murine/in vitro; study design not stated in abstract).

Key Question: What role does JAK3 play in platelet activation and arterial thrombosis via PIP2 generation and calcium signalling?

Key Findings:

• JAK3 regulates platelet PI(4,5)P2 levels, with PIP5K expression implicated per the title.
• JAK3 activity is linked to Ca2+-dependent platelet activation and arterial thrombus formation.
• The abstract provides no quantitative data (effect sizes, models used, sample sizes), so magnitude of effect cannot be assessed.

Clinical Relevance: JAK3 is a potential novel antiplatelet target, and existing JAK inhibitors (used in haematology and rheumatology) could carry thrombotic implications, though no clinical evidence is presented here.

Limitations: The abstract is truncated and gives no methods or data, and findings appear preclinical, so translation to human thrombosis or therapy is unproven.

Study Type: Retrospective cohort study (single-cohort, n=352 newly diagnosed MM) with unsupervised clustering analysis.

Key Question: Does combining soluble BCMA with imaging- and biopsy-derived tumour volume define prognostically distinct phenotypes in newly diagnosed myeloma?

Key Findings:

• sBCMA was the strongest and most consistent prognostic marker, independent of tumour volume (BMPC, MRI-TDV, PET-TMTV).
• Four phenotypes were identified; Sero-dominant (low volume/high sBCMA) and Dual-High groups had similar 12-month PFS despite markedly different tumour volumes, suggesting sBCMA drives early treatment failure.
• Gain(1q21) was strongly adverse in the Sero-dominant phenotype but not significant in the Macro-dominant ("spatially sequestered") phenotype.

Clinical Relevance: A simple serum marker may refine risk stratification beyond conventional imaging and cytogenetics, though sBCMA is not routinely available in NHS practice.

Limitations: The abstract gives no effect sizes, confidence intervals, treatment details or validation cohort, and the PCA-defined phenotypes were derived only in patients with complete datasets, so findings need external validation.

Study Type: Narrative expert review ("How I Treat" article) using four illustrative cases. Not original research; no systematic methodology described.

Key Question: How can MRD testing be used to personalise allogeneic HCT decisions in adults with AML?

Key Findings:

• MRD status in remission stratifies post-HCT relapse and mortality risk, informing patient selection for transplant and conditioning intensity.
• Post-transplant MRD surveillance may allow earlier relapse detection and, in selected patients, guide maintenance or pre-emptive therapy.
• The authors stress important caveats: assay limitations and uncertainty over how to interpret and act on results. No quantitative data are given in the abstract.

Clinical Relevance: Offers practical expert guidance for UK transplant teams considering how to apply MRD results in AML pathways, though access to and standardisation of MRD assays within NHS commissioning may vary.

Limitations: As an expert-opinion piece, recommendations reflect authors' practice rather than prospective trial evidence, and the abstract provides no outcome data.

Study Type: Preclinical laboratory study (CRISPR-engineered human HSPC model with in vitro assays, xenograft engraftment and genomic/proteomic analyses).

Key Question: How does mutant ASXL1 drive transcriptional dysregulation and leukaemogenic phenotypes in human haematopoietic stem and progenitor cells?

Key Findings:

• Truncating ASXL1 mutations stabilised the protein (resistant to proteasomal degradation), reduced differentiation, increased serial replating capacity and improved engraftment in immunodeficient mice.
• Mutant cells showed repression of immediate early genes, subtle global transcriptional upregulation (especially of differentiation-repressed genes), and aberrant RNA polymerase II pausing.
• Increased chromatin binding of RNAPII, BRD4 and MECOM was identified; ASXL1-mutant AML showed increased MECOM activity. Whether the ASXL1–MECOM interaction is direct or indirect remains unresolved.

Clinical Relevance: ASXL1 mutations carry poor prognosis in myeloid malignancies, and this work nominates MECOM and BRD4 as potential therapeutic dependencies, though no clinical application exists yet.

Limitations: Findings derive from engineered cell models and mice, with no treatment testing reported in the abstract, so therapeutic targetability remains unvalidated.

Study Type: Preclinical experimental study (in vitro human/murine platelet assays and in vivo mouse thrombosis models)

Key Question: Does BNP act directly on platelets via its receptor NPRA to promote thrombosis, rather than being solely a biomarker?

Key Findings:

• BNP increased platelet cGMP and enhanced aggregation, granule secretion, spreading and clot retraction in vitro; these effects were abolished in NPRA-deficient platelets.
• BNP administration accelerated thrombus formation in wild-type mice (FeCl₃ carotid injury and thromboplastin-induced pulmonary embolism models), with no effect in NPRA-deficient mice.
• NPRA-deficient mice had prolonged tail bleeding times and delayed arterial occlusion. The abstract gives no quantitative effect sizes.

Clinical Relevance: Raises the hypothesis that elevated BNP/NT-proBNP in heart failure and ACS contributes directly to thrombotic risk, with possible implications for antithrombotic strategies and for patients on sacubitril/valsartan (which raises BNP), though no clinical inference is yet justified.

Limitations: Findings are confined to murine models and ex vivo platelets, with no human clinical data, and the abstract does not state whether BNP concentrations used were pathophysiologically relevant.